# Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE

Study · id `cardio:ct-nct02681016` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02681016](<https://clinicaltrials.gov/study/NCT02681016>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02681016

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 610 participants.

## Technical summary

Registry record NCT02681016. Randomized; single masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2017-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 610 participants (enrolled count; ClinicalTrials.gov record NCT02681016, source copy `cardio:ctgov-nct02681016-2017-12-15`, retrieved 2026-10-26)
- Started: 2015-03 (actual) (ClinicalTrials.gov record NCT02681016, source copy `cardio:ctgov-nct02681016-2017-12-15`, retrieved 2026-10-26)
- Primary completion: 2017-07 (actual) (ClinicalTrials.gov record NCT02681016, source copy `cardio:ctgov-nct02681016-2017-12-15`, retrieved 2026-10-26)
- Completion: 2017-07 (actual) (ClinicalTrials.gov record NCT02681016, source copy `cardio:ctgov-nct02681016-2017-12-15`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT02681016, source copy `cardio:ctgov-nct02681016-2017-12-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02681016-2017-12-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE
- Acronym: PATRIOT
- Condition: Ischemic Heart Disease
- Condition: Coronary Atherosclerosis
- Condition: Coronary Artery Disease
- Condition: Coronary Artery Stenosis
- Intervention (Device): DES "Calypso"
- Intervention (Device): DES "Xience Prime"
- Intervention (Procedure): Coronary angioplasty
- Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
- Lead sponsor class: NETWORK

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Meshalkin Research Institute of Pathology of Circulation (`cardio:org-meshalkin-research-institute-of-pathology-of-circulation`)

## Provenance

Content hash: 6d89b91c51e94ccec1439bf177b975aae00ca09f53bce5c1d724f479042799bf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
